Integrated ⁶⁸Ga-HBED-CC-PSMAPET/MRI in patients with suspected recurrent prostate cancer

Summary

Aim: To evaluate the diagnostic accuracy of FDG PET/CT in the detection of asymptomatic recurrence in patients with malignant melanoma who have had resection of their primary lesion. We also aimed to determine the pattern and factors predisposing to disease recurrence. Methods: Patients with malignant melanoma who have had surgical resection of their disease and without any clinical evidence of disease recurrence were followed- up with FDG PET/CT. The diagnostic accuracy of FDG PET/CT, pattern of recurrence and factors predictive of disease recurrence were determined. Results: A total of 144 patients were followed-up for a median period of 50.50 months. Asymptomatic recurrence was seen in 37 patients (25.7 %) with a median time to recurrence of 20 months. Lymph node was the commonest site of asymptomatic recurrence. Sex, tumour depth, histology type and presence of nodal metastasis were significant predictors of tumour recurrence. Age, race, site of primary lesion, type of lymph node resection were not significant predictors of disease recurrence. Race has a significant effect on the histological subtype of tumour (nodular maligna was more common in Caucasian while acral lentiginous was more prevalent in the Blacks) and the site of the primary lesion (lower limb in Blacks and trunk in Caucasians). Sensitivity, specificity and accuracy of FDG PET/CT for the detection of disease recurrence were 94.5 %, 87.6 % and 89.6 % respectively. Conclusion: FDG PET/CT is a suitable modality for early detection of asymptomatic recurrence of malignant melanoma. Asymptomatic recurrence most commonly occurs in lymph nodes. Sex, nodal metastasis and tumour pathologic features are predictors of recurrence.

Zusammenfassung

Ziel: Ziel der Studie war es, die diagnostischen Genauigkeit des FDG PET/CT beim Nachweis asymptomatischer Rezidive bei Patienten mit malignem Melanom zu untersuchen, deren Primärtumor reseziert wurde. Außerdem sollten das Muster und die für ein Krankheitsrezidiv prädisponierenden Faktoren ermittelt werden. Methoden: Patienten mit malignem Melanom, deren Tumor operativ entfernt wurde und die keine klinischen Anzeichen für ein Rezidiv aufwiesen, wurden mittels FDG PET/CT nachbeobachtet. Die diagnostische Genauigkeit des FDG PET/CT, das Rezidivmuster und die prognostischen Faktoren für ein Krankheitsrezidiv wurden ermittelt. Ergebnisse: Insgesamt wurden 144 Patienten über einen Zeitraum von durchschnittlich 50,5 Monaten nachbeobachtet. Ein asymptomatisches Rezidiv wurde bei 37 Patienten (25,7 %) festgestellt, im Durchschnitt betrug die Zeit bis zum Rezidiv 20 Monate. Die häufigste Lokalisation für ein asymptomatisches Rezidiv waren die Lymphknoten. Geschlecht, Tumortiefe, histologischer Typ und das Vorliegen von Lymphknotenmetastasen waren signifikante Prädiktoren für ein Tumorrezidiv. Alter, ethnische Herkunft, Lokalisation des Primärtumors und Art der Lymphknotenresektion waren nicht signifikante Prädiktoren für ein Krankheitsrezidiv. Die ethnische Herkunft hatte einen signifikanten Effekt auf den histologischen Subtyp des Tumors (das noduläre maligne Melanom trat häufiger bei Kaukasiern auf, das akrolentiginöse Melanom hatte eine höhere Prävalenz bei Schwarzen) und die Lokalisation des Primärtumors (untere Extremität bei Schwarzen, Rumpf bei Kaukasiern). Sensitivität, Spezifität und Genauigkeit des FDG PET/CT beim Nachweis eines Krankheitsrezidivs lagen bei 94,5 %, 87,6 % bzw. 89,6 %. Schlussfolgerung: Das FDG PET/CT eignet sich für den frühen Nachweis von asymptomatischen Rezidiven eines malignen Melanoms. Asymptomatische Rezidive treten am häufigsten in den Lymphknoten auf. Geschlecht, Lymphknotenmetastasen und tumorpathologische Merkmale sind Prädiktoren für ein Rezidiv.

Keywords

PSMA - prostate cancer - PET/MRI - PET/CT

Schlüsselwörter

PSMA - Prostatakarzinom - PET/MRT - PET/CT

• References

• 1 Heidenreich A, Bastian PJ, Bellmunt J. et al. EAU guidelines on prostate Cancer part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014; 65 (01) 124-137.
• 2 Kitajima K, Murphy RC, Nathan MA. Choline PET/CT for imaging prostate cancer: an update. Annals of nuclear medicine. 2013; 27 (07) 581-591.
• 3 Umbehr MH, Muntener M, Hany T. et al. The role of ¹¹C-choline and ¹⁸F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol 2013; 64 (01) 106-117.
• 4 Krause BJ, Souvatzoglou M, Treiber U. Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates. Urol Oncol 2013; 31 (04) 427-435.
• 5 Bauman G, Belhocine T, Kovacs M. et al. ¹⁸F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prost Canc Prost Dis 2012; 15 (01) 45-55.
• 6 Lutje S, Boerman OC, van Rij CM. et al. Prospects in radionuclide imaging of prostate Cancer Prostate. 2012; 72 (11) 1262-1272.
• 7 Silver DA, Pellicer I, Fair WR. et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Canc Res 1997; 3 (01) 81-85.
• 8 Bostwick DG, Pacelli A, Blute M. et al. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998; 82 (11) 2256-2261.
• 9 Minner S, Wittmer C, Graefen M. et al. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate 2011; 71 (03) 281-288.
• 10 Rybalov M, Ananias HJ, Hoving HD. et al. PSMA, EpCAM, VEGF and GRPR as imaging targets in locally recurrent prostate cancer after radiotherapy. Int J Mol Sci 2014; 15 (04) 6046-6061.
• 11 Ananias HJ, van den Heuvel MC, Helfrich W, de Jong IJ. Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer. Prostate 2009; 69 (10) 1101-1108.
• 12 Kawakami M, Nakayama J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Canc Res 1997; 57 (12) 2321-2324.
• 13 Graham K, Lesche R, Gromov AV. et al. Radiofluorinated derivatives of 2-(phosphonomethyl)pentanedioic acid as inhibitors of prostate specific membrane antigen (PSMA) for the imaging of prostate cancer. J Medic Chem 2012; 55 (22) 9510-9520.
• 14 Troyer JK, Beckett ML, Wright Jr. GL. Detection and characterization of the prostate-specific mem brane antigen (PSMA) in tissue extracts and body fluids. Int J Canc 1995; 62 (05) 552-558.
• 15 Afshar-Oromieh A, Avtzi E, Giesel F. et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nuc Med Mol Imag 2015; 42 (02) 197-209.
• 16 Eiber M, Maurer T, Souvatzoglou M. et al. Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nuc Med 2015; 56 (05) 668-674.
• 17 Dietlein M, Kobe C, Kuhnert G. et al. Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer. Mol Imag Biol 2015; 17 (04) 575-584.
• 18 Afshar-Oromieh A, Haberkorn U, Schlemmer HP. et al. Comparison of PET/CT and PET/MRI hybrid systems using a ⁶⁸Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nuc Med Mol Imag 2014; 41 (05) 887-897.
• 19 Freitag MT, Radtke JP, Hadaschik BA. et al. Comparison of hybrid (68)Ga-PSMA PET/MRI and (68)Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. Eur J Nuc Med Mol Imag 2016; 43 (01) 70-83.
• 20 Eiber M, Nekolla SG, Maurer T. et al. (68)Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer. Abdom Imag 2015; 40 (06) 1769-1771.
• 21 Eder M, Schafer M, Bauder-Wust U. et al. ⁶⁸Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 2012; 23 (04) 688-697.
• 22 Drzezga A, Souvatzoglou M, Eiber M. et al. First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nuc Med 2012; 53 (06) 845-855.
• 23 Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 1998; 52 (04) 637-640.
• 24 Rauscher I, Maurer T, Fendler WP. et al. (68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report. Cancer Imag 2016; 16 (01) 14.
• 25 Giesel FL, Hadaschik B, Cardinale J. et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumour lesions in prostate cancer patients. Eur J Nuc Med Mol Imag 2017; 44 (04) 678-688.